Physician profile
Edwin Oghoorian
NPI 1255366779
$2,679.54
in general payments reported to CMS, 2019-2025
20 companies · $83.27 in 2025
The $83.27 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $99.80 · 2021: $369 · 2022: $426 · 2023: $397 · 2024: $1,114 · 2025: $83.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,146 · Travel and Lodging: $447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.40 |
| Travel and Lodging | $447.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,308.29 | 2023-2025 | Navitor, Mitraclip, Portico |
| Paratek Pharmaceuticals, INC. | $433.61 | 2021-2023 | Nuzyra |
| Smith+Nephew, INC. | $244.17 | 2019-2024 | Collagenase Santyl, Grafix, Regranex |
| Integra Lifesciences Corporation | $115.55 | 2019-2023 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Horizon Therapeutics Plc | $96.41 | 2020-2023 | Krystexxa |
| Medtronic, INC. | $83.40 | 2022-2023 | Accurian |
| Abbvie INC. | $78.02 | 2021-2022 | |
| In2bones USA, LLC | $61.29 | 2022 | |
| Bioventus LLC | $44.38 | 2022 | |
| Merck Sharp & Dohme LLC | $35.44 | 2019 | |
| Kci USA, INC. | $30.23 | 2023 | Promogran Prisma, Kerramax Care |
| Vertex Pharmaceuticals Incorporated | $21.90 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $20.93 | 2023 | Seglentis |
| Acell, INC. | $18.24 | 2019 | |
| Arthrosurface Incorporated | $16.44 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $16.03 | 2023 | Senza |
| Medtronic Vascular, INC. | $15.89 | 2020 | |
| Paragon 28, INC. | $14.69 | 2019 | |
| Nabriva Therapeutics, Plc | $14.28 | 2020 | |
| Organogenesis INC. | $10.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Oghoorian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.